446 related articles for article (PubMed ID: 26467654)
21. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
Gürcan HM; Ahmed AR
Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
[TBL] [Abstract][Full Text] [Related]
22. Immunoglobulin Treatment in Neuromuscular Medicine.
Burakgazi AZ
J Clin Neuromuscul Dis; 2019 Jun; 20(4):182-193. PubMed ID: 31135621
[TBL] [Abstract][Full Text] [Related]
23. Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions.
Bichuetti-Silva DC; Furlan FP; Nobre FA; Pereira CT; Gonçalves TR; Gouveia-Pereira M; Rota R; Tavares L; Mazzucchelli JT; Costa-Carvalho BT
Int Immunopharmacol; 2014 Dec; 23(2):442-6. PubMed ID: 25257732
[TBL] [Abstract][Full Text] [Related]
24. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy.
Cocito D; Paolasso I; Antonini G; Benedetti L; Briani C; Comi C; Fazio R; Jann S; Matà S; Mazzeo A; Sabatelli M; Nobile-Orazio E;
Eur J Neurol; 2010 Feb; 17(2):289-94. PubMed ID: 19863650
[TBL] [Abstract][Full Text] [Related]
25. Intravenous immunoglobulin in paediatric neurology: safety, adherence to guidelines, and long-term outcome.
Nosadini M; Mohammad SS; Suppiej A; Sartori S; Dale RC;
Dev Med Child Neurol; 2016 Nov; 58(11):1180-1192. PubMed ID: 27242065
[TBL] [Abstract][Full Text] [Related]
26. Octagam
Wietek S
Neurodegener Dis Manag; 2018 Aug; 8(4):227-231. PubMed ID: 29517417
[TBL] [Abstract][Full Text] [Related]
27. Severe Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following High-dose (3 g/kg) Intravenous Immunoglobulin Therapy.
Seino Y; Nakamura T; Hirohata M; Kawarabayashi T; Okushima T; Shoji M
Intern Med; 2019 Mar; 58(6):855-859. PubMed ID: 30449785
[TBL] [Abstract][Full Text] [Related]
28. Intravenous immunoglobulin in autoimmune neuromuscular diseases.
Dalakas MC
JAMA; 2004 May; 291(19):2367-75. PubMed ID: 15150209
[TBL] [Abstract][Full Text] [Related]
29. Early platelet and leukocyte decline in patients with neuroinflammatory disorders after intravenous immunoglobulins.
Totzeck A; Stettner M; Hagenacker T
Eur J Neurol; 2017 Apr; 24(4):638-644. PubMed ID: 28224702
[TBL] [Abstract][Full Text] [Related]
30. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.
Hughes RA; Gorson KC; Cros D; Griffin J; Pollard J; Vallat JM; Maurer SL; Riester K; Davar G; Dawson K; Sandrock A;
Neurology; 2010 Feb; 74(8):651-7. PubMed ID: 20177118
[TBL] [Abstract][Full Text] [Related]
31. Long term safety of IVIg therapy in multiple sclerosis: 10 years experience.
Katz U; Kishner I; Magalashvili D; Shoenfeld Y; Achiron A
Autoimmunity; 2006 Sep; 39(6):513-7. PubMed ID: 17060031
[TBL] [Abstract][Full Text] [Related]
32. Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulins.
Ritter C; Bobylev I; Lehmann HC
J Neuroinflammation; 2015 Aug; 12():148. PubMed ID: 26268846
[TBL] [Abstract][Full Text] [Related]
33. [The rational immunotherapy with intravenous immunoglobulin in neurologic diseases].
Korsak J
Pol Merkur Lekarski; 2011 Jun; 30(180):430-4. PubMed ID: 21751554
[TBL] [Abstract][Full Text] [Related]
34. Clinical applications of intravenous immunoglobulins in neurology.
Hughes RA; Dalakas MC; Cornblath DR; Latov N; Weksler ME; Relkin N
Clin Exp Immunol; 2009 Dec; 158 Suppl 1(Suppl 1):34-42. PubMed ID: 19883422
[TBL] [Abstract][Full Text] [Related]
35. Intravenous immunoglobulin: adverse effects and safe administration.
Orbach H; Katz U; Sherer Y; Shoenfeld Y
Clin Rev Allergy Immunol; 2005 Dec; 29(3):173-84. PubMed ID: 16391392
[TBL] [Abstract][Full Text] [Related]
36. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone.
Lopate G; Pestronk A; Al-Lozi M
Arch Neurol; 2005 Feb; 62(2):249-54. PubMed ID: 15710853
[TBL] [Abstract][Full Text] [Related]
37. Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections.
Günther G; Dreger B
Microbiol Immunol; 2013 Jul; 57(7):527-35. PubMed ID: 23607863
[TBL] [Abstract][Full Text] [Related]
38. [Exfoliative dermatitis as a side effect of intravenous immunoglobulin treatment].
Markvardsen LH; Jakobsen J
Ugeskr Laeger; 2011 Oct; 173(43):2725-6. PubMed ID: 22027232
[TBL] [Abstract][Full Text] [Related]
39. Intravenous immunoglobulin treatment in peripheral nerve disorders--indications, mechanisms of action and side-effects.
Hahn AF
Curr Opin Neurol; 2000 Oct; 13(5):575-82. PubMed ID: 11073366
[TBL] [Abstract][Full Text] [Related]
40. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature.
Marie I; Maurey G; Hervé F; Hellot MF; Levesque H
Br J Dermatol; 2006 Oct; 155(4):714-21. PubMed ID: 16965420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
